Evaxion to present a full clinical readout on two personalized cancer immunotherapies in q2 2023

Copenhagen, denmark, dec. 15, 2022 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies, today announced that they expect to present data from their two clinical trials of personalized cancer immunotherapies (cancer vaccines) evx-01 and evx-02 in the second quarter of 2023.
EVAX Ratings Summary
EVAX Quant Ranking